Darzalex Faspro (Daratumumab and Hyaluronidase-fihj): Uses, Side Effects & Warnings

• Darzalex Faspro is a combination of daratumumab and hyaluronidase-fihj, primarily used to treat multiple myeloma.
• It targets CD38 protein on myeloma cells, leading to their destruction through various immune mechanisms.
• The medication is administered via subcutaneous injection, offering a quicker and more convenient option compared to intravenous infusions.
• Common side effects include injection site reactions, fatigue, and nausea, while serious risks involve infections and blood count abnormalities.
• Close monitoring by a healthcare professional is essential throughout treatment to manage potential adverse effects and ensure patient safety.

What is Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Used For?

Darzalex Faspro (daratumumab and hyaluronidase-fihj) is an important therapeutic agent specifically indicated for the treatment of multiple myeloma, a cancer of plasma cells found in the bone marrow. This condition is characterized by the uncontrolled proliferation of abnormal plasma cells, which can lead to bone damage, kidney problems, anemia, and frequent infections. The approval of Darzalex Faspro has provided a valuable option for patients at various stages of this complex disease.

The Darzalex Faspro uses span across different treatment settings, including newly diagnosed patients and those with relapsed or refractory multiple myeloma. It is often administered in combination with other anti-myeloma agents, such as lenalidomide, bortezomib, carfilzomib, pomalidomide, or dexamethasone, to enhance its efficacy. This combination approach aims to target the cancer cells through multiple pathways, improving response rates and progression-free survival for patients.

Specifically, Darzalex Faspro is approved for:

• Newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone in patients who are not candidates for autologous stem cell transplant.
• Newly diagnosed multiple myeloma in combination with bortezomib, melphalan, and prednisone in patients who are not candidates for autologous stem cell transplant.
• Relapsed/refractory multiple myeloma as a monotherapy after at least three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, or if patients are double-refractory to a proteasome inhibitor and an immunomodulatory agent.
• Relapsed/refractory multiple myeloma in combination with pomalidomide and dexamethasone, or with carfilzomib and dexamethasone, or with bortezomib and dexamethasone, in patients who have received at least one prior therapy.

Mechanism of Action and Drug Information for Darzalex Faspro

Understanding the mechanism of action and drug information for Darzalex Faspro is crucial for appreciating its role in treating multiple myeloma. This medication combines two active components: daratumumab, a monoclonal antibody, and hyaluronidase-fihj, an enzyme that facilitates subcutaneous delivery. This innovative formulation allows for a more convenient administration route while maintaining the therapeutic benefits of daratumumab.

The primary therapeutic component, daratumumab, is a CD38-directed cytolytic antibody. CD38 is a highly expressed transmembrane glycoprotein on the surface of multiple myeloma cells, making it an ideal target for therapeutic intervention. Daratumumab binds specifically to CD38, initiating a cascade of immune-mediated cell death mechanisms that effectively eliminate myeloma cells. These mechanisms include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and direct apoptosis induction.

How does Darzalex Faspro work?

Darzalex Faspro (daratumumab and hyaluronidase-fihj) works by leveraging the targeted action of daratumumab against CD38-positive multiple myeloma cells. Once daratumumab binds to CD38, it recruits various immune effector cells, such as natural killer (NK) cells and macrophages, to destroy the cancer cells. It also activates the complement system, leading to the lysis of myeloma cells. Additionally, daratumumab can directly induce programmed cell death (apoptosis) in CD38-expressing tumor cells. The hyaluronidase-fihj component in Darzalex Faspro is an enzyme that temporarily breaks down hyaluronan in the subcutaneous tissue, allowing for greater dispersion and absorption of daratumumab, which enables its administration as a rapid subcutaneous injection rather than a prolonged intravenous infusion.

Key Drug Information

Darzalex Faspro is administered as a subcutaneous injection, typically by a healthcare professional. The recommended dosage and frequency depend on the specific treatment regimen and whether it is used as monotherapy or in combination with other drugs. For instance, initial treatment may involve weekly injections, gradually transitioning to less frequent administration, such as every two or four weeks. Patients receive pre-medications (e.g., corticosteroids, antihistamines, antipyretics) to reduce the risk of infusion-related reactions, although these reactions are generally less common and less severe with subcutaneous administration compared to intravenous daratumumab.

The subcutaneous formulation offers a significant advantage in terms of administration time, reducing it from several hours for intravenous daratumumab to approximately 3-5 minutes. This improvement in convenience can greatly enhance the patient experience and reduce the burden on healthcare facilities. As with all oncology treatments, careful monitoring of blood counts and patient response is essential throughout the course of therapy to ensure optimal outcomes and manage any potential adverse effects.

Darzalex Faspro Side Effects and Warnings

Like all medications, Darzalex Faspro (daratumumab and hyaluronidase-fihj) can cause side effects, and it comes with specific warnings and precautions that patients and healthcare providers should be aware of. The safety profile is generally consistent with that of intravenous daratumumab, with the added consideration of injection site reactions due to the subcutaneous route.

It is crucial for patients to report any new or worsening symptoms to their doctor immediately. Healthcare professionals will monitor patients closely for adverse reactions throughout the treatment period. The following sections detail common side effects and important warnings associated with Darzalex Faspro.

Common Side Effects

The most frequently reported Daratumumab and Hyaluronidase-fihj side effects are generally mild to moderate and manageable. These often include:

• Injection Site Reactions: Pain, redness, swelling, itching, or bruising at the site of injection are common. These are usually mild and resolve on their own.
• Fatigue: Feeling tired or lacking energy is a very common side effect of many cancer treatments, including Darzalex Faspro.
• Nausea and Diarrhea: Gastrointestinal disturbances are frequently reported.
• Upper Respiratory Tract Infection: Patients may experience symptoms like a runny nose, sore throat, or cough.
• Cough: Persistent coughing can occur.
• Fever: An elevated body temperature may be experienced.
• Peripheral Neuropathy: Numbness, tingling, or pain in the hands or feet, especially when used in combination with bortezomib.

These side effects are typically managed with supportive care, and their incidence may vary depending on whether Darzalex Faspro is used as monotherapy or in combination with other drugs.

Serious Warnings and Precautions

Several serious Darzalex Faspro warnings and precautions require careful attention:

Infusion-Related Reactions: Although less common and generally milder with subcutaneous administration compared to intravenous daratumumab, infusion-related reactions can still occur. These typically manifest within 24 hours of administration and may include symptoms such as shortness of breath, dizziness, cough, rash, or chills. Patients are pre-medicated to reduce this risk, and healthcare providers are prepared to manage such reactions promptly.

Hematologic Toxicities: Darzalex Faspro can cause significant decreases in blood cell counts, including neutropenia (low white blood cells, increasing infection risk) and thrombocytopenia (low platelets, increasing bleeding risk). Regular complete blood count monitoring is essential throughout treatment to detect and manage these toxicities. Dose adjustments or growth factor support may be necessary.

Infections: Due to its immunosuppressive effects, Darzalex Faspro increases the risk of serious infections, including bacterial, viral, and fungal infections. Pneumonia, bronchitis, and upper respiratory tract infections are particularly common. Patients should be monitored for signs and symptoms of infection and treated promptly if an infection develops. Prophylactic antiviral medication may be considered for patients at risk of herpes zoster reactivation.

Hepatitis B Reactivation: In patients with a history of Hepatitis B virus (HBV) infection, reactivation can occur. Patients should be screened for HBV infection before starting treatment, and those with positive serology should be monitored for signs of reactivation during and after therapy.

Progressive Multifocal Leukoencephalopathy (PML): PML is a rare but serious and potentially fatal viral infection of the brain. While rare, cases have been reported with daratumumab. Patients should be monitored for new or worsening neurological symptoms, and if PML is suspected, treatment should be withheld.

Interference with Serological Testing: Daratumumab binds to CD38 on red blood cells, which can interfere with indirect antiglobulin tests (Coombs test) and cross-matching, potentially leading to false-positive results. Blood banks should be informed that a patient is receiving Darzalex Faspro to ensure accurate blood typing and cross-matching procedures.

Embryo-Fetal Toxicity: Darzalex Faspro can cause fetal harm when administered to a pregnant woman. Women of reproductive potential should use effective contraception during treatment and for 3 months after the last dose. It is not known whether Darzalex Faspro is excreted in human milk, so women should not breastfeed during treatment and for 3 months after the last dose.

Frequently Asked Questions

What is the main advantage of Darzalex Faspro over intravenous daratumumab?

The primary advantage of Darzalex Faspro is its subcutaneous administration, which significantly reduces the treatment time. While intravenous daratumumab infusions can take several hours, Darzalex Faspro can be administered in approximately 3-5 minutes. This convenience greatly improves the patient experience, reduces the burden on healthcare facilities, and allows for more flexible scheduling, enhancing overall adherence to treatment regimens for multiple myeloma.

How is Darzalex Faspro administered?

Darzalex Faspro is administered as a subcutaneous injection, typically into the abdomen, by a healthcare professional. Unlike intravenous infusions that require a vein, the subcutaneous route involves injecting the medication just under the skin. Patients usually receive pre-medications, such as corticosteroids, antihistamines, and fever reducers, prior to the injection to minimize the risk of potential injection-related reactions, ensuring a safer and more comfortable experience.

What should patients watch out for after receiving Darzalex Faspro?

After receiving Darzalex Faspro, patients should be vigilant for several potential reactions. Common concerns include injection site reactions like pain, redness, or swelling. Patients should also monitor for signs of infection, such as fever, chills, or unusual fatigue, due to the increased risk of immunosuppression. Any symptoms of an allergic reaction, such as difficulty breathing, rash, or dizziness, should be reported to a healthcare provider immediately, even if delayed.